Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025

Rhea-AI Summary

Abpro (Nasdaq: ABP) announced its previously approved 1-for-30 reverse stock split became effective Oct 31, 2025 and trading will be split-adjusted at the open on Nov 3, 2025. At the effective time every 30 shares combined into one; the company will not issue fractional shares and fractions will be rounded up.

Outstanding shares will fall from ~81.2 million to 2.7 million. Options and warrants will be proportionally adjusted. The company cited the Reverse Stock Split as a step to maintain Nasdaq compliance while pursuing a capital-efficient growth phase after an estimated ~60% reduction in operating costs. Celltrion will fund all development expenses for lead program ABP-102, with a first-in-human trial anticipated in 2026.

Positive

• Outstanding shares reduced from 81.2M to 2.7M
• Operated with an estimated ~60% reduction in operating costs versus 2024
• Celltrion funds all development expenses for lead program ABP-102
• ABP-102 first-in-human trial anticipated in 2026

Negative

• Reverse split required to maintain Nasdaq listing, implying prior noncompliance risk
• Share consolidation may reduce public float and lower daily liquidity

Insights

Senior biotech analyst

Reverse split secures Nasdaq compliance; cost cuts and partner-funded development limit near-term cash needs but meaningful milestones still pending.

The 1-for-30 reverse split reduced outstanding shares from ~81.2 million to ~2.7 million and becomes effective at 5:01 p.m. ET on October 31, 2025, with split-adjusted trading beginning November 3, 2025. This action directly addresses listing compliance and reduces the share count, which can simplify capital-raising mechanics and improve per-share metrics without changing the company’s cash position.

Operationally, the company reports an estimated 60% reduction in operating costs versus the comparable period in 2024 and states that Celltrion funds all development expenses for the lead program ABP-102 while Abpro retains commercial/economic rights. Those facts reduce near-term cash burn and transfer development expense risk to the partner, but do not by themselves create new revenue or guarantee clinical success.

Key items to watch: initiation of the first-in-human trial for ABP-102 in 2026, any disclosures of remaining cash runway or new financing plans, and updates on the Celltrion funding arrangement or economic terms. Expect meaningful investor reaction around trial start dates and any future funding or milestone notices over the next 6–12 months.

11/03/2025 - 07:00 AM

Achieved ~60% reduction in operating costs through a focused cost optimization plan

DiversImmune^® platform positioned to unlock additional pipeline value

Reverse stock split supports Nasdaq compliance and positions company for next phase of growth

BURLINGTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today announced that its previously approved 1-for-30 reverse stock split (the “Reverse Stock Split”) of its common stock became effective at 5:01 p.m. Eastern Time on October 31, 2025. The Company’s common stock will begin trading on a split-adjusted basis at the open of trading on November 3, 2025 under the ticker symbol “ABP” and the new CUSIP number will be 000847202.

At the effective time, every 30 shares of issued and outstanding common stock will automatically combine into one (1) issued and outstanding share. No fractional shares will be issued as a result of the Reverse Stock Split; stockholders otherwise entitled to a fractional share will receive an additional fraction rounded up to the next whole share. Following the Reverse Stock Split, the number of shares of common stock outstanding will be reduced from approximately 81.2 million to 2.7 million. Shares underlying the Company’s outstanding stock options and warrants will be proportionally adjusted, along with corresponding exercise prices.

The Company’s transfer agent, Continental Stock Transfer & Trust Company, will serve as the exchange agent for the Reverse Stock Split.

“This action is a highly necessary step in our efforts to maintain our Nasdaq listing and reflects a broader realignment of Abpro for the future,” said Miles Suk, Chief Executive Officer and Chairman of Abpro. “With a leaner cost structure, a major global partner in Celltrion, and a differentiated antibody platform, we are positioned to execute more effectively and create long-term value for our shareholders.”

Positioned for Growth and Value Creation

The Reverse Stock Split positions Abpro to reach compliance with Nasdaq as the Company enters a more focused and capital-efficient phase of growth. Over the past few quarters, Abpro has achieved an estimated ~60% reduction in operating costs versus the same period in 2024 through disciplined execution and streamlined operations.

The Company’s partnership with Celltrion remains a key strategic advantage. Celltrion funds all development expenses for Abpro’s lead antibody program ABP-102, while Abpro retains meaningful commercial and economic rights. A first-in-human trial for ABP-102 is anticipated in 2026.

Abpro is also evaluating its broader pipeline to unlock additional value through its DiversImmune^® and MultiMab^TM platforms, which together enable the rapid creation of bispecific and multispecific antibodies with enhanced selectivity and safety.

About Abpro
Abpro’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using Abpro's proprietary DiversImmune^® platform. Abpro is located in Woburn, Massachusetts. For more information, please visit www.abpro.co.

Forward Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, and expectations regarding the therapeutic benefit of Abpro’s programs, as well as strategic partnerships. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; Abpro’s ability to continue as a going concern; Abpro’s ability to achieve compliance with Nasdaq listing standards; expectations regarding the therapeutic benefit of Abpro’s programs; that final data from Abpro’s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; Abpro’s ability to efficiently discover and develop product candidates; Abpro’s ability to obtain and maintain regulatory approval of product candidates; Abpro’s ability to maintain its intellectual property; the implementation of Abpro’s business model, including strategic plans for Abpro’s business and product candidates; and other risks identified in Abpro’s filings with the U.S. Securities and Exchange Commission (SEC) including Abpro’s most recent Annual Report on Form 10-K filed with the SEC and subsequent filings with the SEC. Abpro cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Abpro disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Abpro’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor and Media Contact:
Daniel Kontoh-Boateng
DKB Partners, LLC
Tel: +1-862-213-1398
dboateng@dkbpartners.net

FAQ

What exact reverse stock split did Abpro (ABP) implement and when did it take effect?

Abpro implemented a 1-for-30 reverse stock split effective at 5:01 p.m. ET on Oct 31, 2025, trading split-adjusted on Nov 3, 2025.

How many Abpro (ABP) shares will be outstanding after the Nov 3, 2025 Reverse Stock Split?

Outstanding shares will be reduced from approximately 81.2 million to 2.7 million after the Reverse Stock Split.

Will Abpro (ABP) issue fractional shares after the 1-for-30 reverse split?

No fractional shares will be issued; holders otherwise entitled to fractions will have their shares rounded up to the next whole share.

What impact does the Reverse Stock Split have on Abpro (ABP) options and warrants?

Shares underlying outstanding options and warrants will be proportionally adjusted along with corresponding exercise prices.

How does Abpro (ABP) plan to fund development of its lead program ABP-102?

Celltrion will fund all development expenses for ABP-102 while Abpro retains meaningful commercial and economic rights.

What operational progress did Abpro (ABP) report alongside the reverse split on Nov 3, 2025?

The company reported an estimated ~60% reduction in operating costs versus the same period in 2024.